Income Taxes - Net operating losses (Details) - USD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Income Taxes | ||
| Accrued interest or penalties related to uncertain tax positions | $ 0 | |
| Income tax examination, penalties and interest expense | $ 0 | |
| Income Tax Examination, Description | The Company will recognize interest and penalties related to uncertain tax positions as a component of interest income, net. As of December 31, 2025, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statement of operations. Tax years from 2022 and after remain subject to examination by the taxing jurisdictions. The NOL and tax credit carryforwards remain subject to review until utilized. | |
| Income Tax Examination, Year under Examination | 2021 2022 2023 2024 2025 | |
| Research tax credits | ||
| Income Taxes | ||
| Research tax credits | $ 55,020 | $ 50,842 |
| Domestic Tax Jurisdiction [Member] | ||
| Income Taxes | ||
| Net operating loss carryforwards subject to expiration | 300 | |
| Federal | ||
| Income Taxes | ||
| Net operating loss carryforwards | 398,039 | 339,055 |
| Federal | Research tax credits | ||
| Income Taxes | ||
| Research tax credits | 11,600 | |
| Federal | Orphan drug | ||
| Income Taxes | ||
| Research tax credits | 43,400 | |
| State | ||
| Income Taxes | ||
| Net operating loss carryforwards | 398,035 | 339,051 |
| Local | ||
| Income Taxes | ||
| Net operating loss carryforwards | $ 277,828 | $ 218,844 |